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Abstract
Background: Alcohol-related harm is currently estimated to cost the National Health Service (NHS) in England £3.5 bn a
year. Of the estimated 1.6 million people with some degree of alcohol dependence, some 600,000 are believed to be
moderately or severely dependent and may benefit from intensive treatment. Outcomes from medically assisted
withdrawal, also referred to as detoxification, are often poor, with poor engagement in relapse prevention interventions
and subsequent high relapse rates. Detoxification is costly both financially and to the individual. It has been found that
people who experience multiple detoxifications show more emotional and cognitive impairments. These changes may
confer upon them the inability to resolve conflict and increased sensitivity to stress thus contributing to increased
vulnerability risk of relapse. The study aims to test the feasibility of using a group intervention aiming to prepare
participants for long-term abstinence before, rather than after, they have medically assisted detoxification. The current
study will establish key parameters that influence trial design such as recruitment, compliance with the intervention,
retention, and sensitivity of alternative outcome measures, in preparation for a future randomised controlled trial (RCT).
This paper presents the protocol of the feasibility study.
Methods: The study corresponds to phase 2 of the Medical Research Council (MRC) complex interventions guidelines which
cover the development and feasibility testing of an intervention. The work is in three stages. The development, adaptation
and implementation of the Structured Preparation before Alcohol Detoxification (SPADe) intervention (stage 1), a randomised
feasibility study with economic evaluation (stage 2) and a qualitative study (stage 3). Fifty participants will be recruited from
two community alcohol treatment services in England. Participants will be randomised in two arms: the treatment as usual
arm (TAU), which includes planned medically assisted detoxification and aftercare and the intervention arm in which
participants will receive structured group preparation before detoxification in addition to TAU. The main outcomes are
duration of continuous abstinence with no incidents of lapse or relapse, percentage of days abstinent and time to relapse.
Discussion: The socioeconomic harms associated with alcohol have been well-documented, yet existing treatment options
have not been able to reduce high relapse rates. This study will build on existing naturalistic studies underpinned by
psychological interventions offered early and before detoxification from alcohol, which aim to reverse automatised habitual
behaviours and thus may help us to understand how better to support people to remain abstinent and improve post
detoxification outcomes.
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Background
Tackling the impact of harmful and dependent drinking
is a key global public health priority. Harmful drinking
refers to consuming alcohol at amount and patterns that
would affect the person’s physical and mental health and
lead to personal and social harm. The harm is linked to
both chronic as well as episodic heavy use (intoxication).
For example, global estimates suggest that one in five
adults report at least one occasion of heavy episodic
drinking in the past month [1]. Alcohol harmful use is
linked directly to a range of health disorders, including
high blood pressure, heart disease, stroke, liver disease,
some cancers and depression [2]. Furthermore, more
than 21,000 people died from alcohol-related causes in
England in 2012 [2]. As far as financial cost is con-
cerned, estimates suggest that alcohol-related harm
(from harmful and dependent use) costs the National
Health Service (NHS) in England £3.5 bn a year [2].
Despite the fact that the prevalence of dependent drink-
ing is far less than that of harmful drinking, of an esti-
mated 1.6 million people with some degree of alcohol
dependence, some 600,000 are believed to be moderately
or severely dependent and may benefit from intensive
treatment [3]. Individuals who are ‘moderately’ or ‘se-
verely’ dependent represent the severe end of the
spectrum of alcohol use disorders and consume alcohol at
levels that are likely to have a severe impact on their own
health and mortality, the health and behaviours of others
(family members) and to have economic and social impli-
cations [4]. Alcohol dependence impacts significantly on
the NHS, as individuals affected are at increased risk of ac-
cidents, and more likely to attend an accident and emer-
gency department (A&E) and have emergency admissions
[2, 5]. In the longer term, alcohol-dependent individuals
are more likely to suffer from chronic conditions requiring
expensive treatment, such as liver and heart disease [2].
Current treatment guidelines suggest that treatment for
moderate to severe alcohol dependence needs to be
planned, with up to four motivational sessions focusing on
treatment engagement and development of aftercare sup-
port, followed by medically assisted withdrawal (also re-
ferred to as detoxification) and aftercare support [4].
Benzodiazepines are normally prescribed during detoxifica-
tion to reduce the overt symptoms of alcohol withdrawal
(sweats, tremor) as well as potentially life-threatening com-
plications (e.g. convulsions, delirium tremens) [4]. However,
these drugs do not prevent alcohol craving, relapse back
into alcohol drinking and other long-term effects on mental
functioning [4, 6]. Outcomes from detoxification are often
poor with low proportions engaging in aftercare [7] and
high relapse rates [4]. Repeat detoxification is costly. Add-
itionally, there is some evidence suggesting that people with
alcohol dependence who experience multiple detoxifica-
tions show increased impairment in mental functioning [8,
9]. It is important to clarify that these changes are shown to
be associated, not caused by the detoxification process.
Nevertheless, they may confer inability in conflict reso-
lution and increased sensitivity to stress, both of which may
contribute to relapse and might compromise the effective-
ness of aftercare support [8–11]. There is also evidence to
suggest that multiple detoxifications can exacerbate craving,
adversely impacting on subsequent attempts at achieving
abstinence [12].
In the light of the abovementioned evidence indicating
the potential risk of an accumulation of adverse effects
following repeated detoxifications, and until definitive
evidence is generated to confirm or refute a causal rela-
tionship, it is prudent to maximise treatment effective-
ness and to reduce the risk of exposing people to
repeated detoxifications and the potential adverse effects
associated with the detoxification process itself. Al-
though the existing evidence is only indicative, it is pos-
sible that the long-term course, and economic and social
impact of alcohol dependence, is not only due to the
natural process of the phenomenon, but is also associ-
ated with the existing treatment approach that empha-
sises the importance of the provision of detoxification
per se, without any emphasis on long-term sustainable
outcomes. There is currently no guidance specifically on
preparation for the detoxification process, apart from
general guidance on care coordination and case manage-
ment [4]. Absence of specific guidance reflects the lack
of developed interventions in this area. Evidence is re-
quired on whether structured preparation before detoxi-
fication rather than detoxification alone improves
treatment outcomes and therefore whether the whole
treatment paradigm should shift. Before embarking on a
full trial of the effectiveness of such structured prepar-
ation, there is a need to undertake a feasibility study to
establish key parameters that influence trial design such
as recruitment, adherence to the intervention, retention
and sensitivity of alternative outcome measures.
A literature search of PubMed Central using alcohol re-
lapse prevention, treatment-related MeSH terms under-
taken in June 2014 found (1) that group interventions
with diverse theoretical bases are considered to be more
cost-effective than one-to-one interventions [13] and (2)
cognitive behaviour therapy (CBT) relapse prevention in-
terventions are well-supported by evidence [14].
In the UK, an innovative group intervention for prep-
aration before alcohol detoxification, based on CBT re-
lapse prevention interventions, developed by members
of the research team, reduced detox dropouts [15] and
improved outcomes at 1, 3 [5] and 6months [16]. How-
ever, these findings were from small naturalistic studies.
Qualitative evidence found that ‘regaining control’ was
the main learning point across all group sessions of the
programme [17].
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This proposed feasibility study builds on the above
preliminary evidence and aims to refine the preparatory
intervention and assess the feasibility of conducting a
large-scale evaluation (Structured Preparation before Al-
cohol Detoxification (SPADe)) for people with moderate
to severe alcohol dependence, as an adjunct to usual
care, consisting of planned detoxification and aftercare.
The intervention under investigation in this study is
based on Plans, Responses, Impulses, Motives, Evaluations
(PRIME) theory of motivation [18] and learning theories
[19] that underlie the use of psychological interventions
aiming to reverse the development of automatised behav-
iour and associated loss of control, such as CBT relapse
prevention interventions. It combines the long-established
(in alcohol treatment) ethos of group intervention and fol-
lows the biological principle of homeostasis, which is dis-
turbed with prolonged alcohol use [20], in order to help
individuals to regain control over drinking as the first step
towards lifelong sustainable abstinence.
Aims and objectives
The key research question is can we design a large-scale,
randomised controlled trial (RCT) that will answer
whether SPADe as an adjunct to usual care is more ef-
fective than usual care alone in helping adults to main-
tain longer periods of alcohol abstinence? The feasibility
trial will compare the use of SPADe as an adjunct to
treatment as usual with treatment as usual in the partici-
pating sites.
Furthermore, reduction in subjective measures of alco-
hol dependence and craving as well as improvement in
objective measures of mental functioning will be ex-
plored. Finally, we will conduct qualitative interviews
with service users, their carers and service providers, to
assess the acceptability of the treatment and to explore
their experience of the treatment including any barriers
and/or facilitators to taking part in the study. Findings
from these interviews will enable us to refine the SPADe
intervention and the design of the future definitive RCT.
Methods/design
The study corresponds to Phase 2 of the Medical Re-
search Council (MRC) complex interventions guidelines,
which guides the development of an intervention [21].
Therefore, the study has three stages:
Stage 1—adaptation and implementation of the
intervention
We will adapt the existing pre-alcohol detox group proto-
col [6, 16, 17] by incorporating feedback from service
users and group facilitators gathered at two patient and
public involvement (PPI) meetings to produce a manual
for the intervention. Group facilitators will be recruited
from existing staff and trained in the intervention via the
use of the manual. When training is complete, we will im-
plement the SPADe groups across our two study sites.
A 1-day training event will take place in each partici-
pating site and one central event for those not able to at-
tend locally. At least six members of staff will be trained
(to allow cross-cover for sickness and leave). Facilitators
will have face-to-face or Skype supervision at least
monthly or more frequently if required weekly by the
chief investigator.
Importantly during this phase, treatment as usual proce-
dures will also be standardised across the sites. To reduce
the risk of contamination between the intervention and
the control arms of the study, the trained intervention
group facilitators will offer only the intervention and they
will not undertake individual work with any service user
for the period of the study. They will also provide the
one-to-one version of the intervention to non-English
speaking service users (via an interpreter if required). The
rest of the staff will provide the treatment as usual.
Stage 2—feasibility study
Design
This is a single-blind (outcome assessor blind to alloca-
tion), parallel, two-arm, feasibility RCT comparing the
clinical effectiveness of SPADe as an adjunct to treat-
ment as usual (TAU), against TAU. Participants will be
assessed at baseline, 3, 6 and 12 months following ran-
domisation. Additionally, qualitative interviews will be
carried out at 3 and 9months (see stage 3 below).
Setting
Participants will be recruited from specialist alcohol
community services offering recovery-orientated treat-
ment for people with alcohol use disorders (AUD). Re-
cruitment will take place in two sites, both offering the
intervention and the treatment as usual, in order to ex-
plore challenges associated with implementation of the
intervention across a range of services.
Participants
We will recruit 50 alcohol-dependent participants, aged
18 or over who have a desire to stop drinking. As both
recruiting services operate within a multi-lingual,
multi-faith and multi-cultural environment, we will pro-
vide study information in the two most prevalent lan-
guages spoken by non-English speakers in our locations,
in addition to the material in English. Should we recruit
any non-English speaking participants to the interven-
tion arm, the sessions will be provided in one-to one for-
mat by the intervention group facilitator, with the
support of an interpreter if required. Participant flow to
the study is shown in Fig. 1. We will aim to recruit at
least one of the above participants in the qualitative
study to explore their experience.
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Recruitment
When entering the service, eligible service users will be
advised about the study by the clinician undertaking the
initial assessment, following the completion of the as-
sessment. If interested, the service user will be given the
participant information sheet and a member of the re-
search team will contact them a few days later to ascer-
tain if they would like to be recruited into the study. An
arrangement will be made to meet in the clinic to take
informed consent and collect baseline information.
Participants will receive a £10 shopping voucher (not
valid for alcohol purchase) per completion of each re-
search assessment throughout the trial (four in total,
with additional two vouchers if they take part in the
qualitative study, see below) (see Fig. 1).
Inclusion criteria
Inclusion criteria are as follows:
1. Presentation to either of the two alcohol services
seeking abstinence from alcohol.
2. Alcohol dependence (moderate to severe), scoring
16 and above on Severity of Alcohol Dependence
Questionnaire (SADQ) (see the ‘Outcome measures’
section below). This level of dependence indicates
that it would be clinically appropriate to receive a
medically assisted detoxification [4].
3. Stated intention to stay in the area within the time
period of the intervention.
4. Willingness to be part of a group intervention if
randomised to receive it.
Exclusion criteria
Exclusion criteria are as follows:
1. Age less than 18 (as not usually treated by specialist
alcohol services).
Fig. 1 Recruitment and follow-up flow diagram
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2. Pregnancy: pregnant women need urgent
intervention to withdraw from alcohol, due to the
effect of alcohol on the foetus.
3. Known terminal illness with life expectancy of less
than 6 months.
4. Severe medical condition that requires urgent
medical admission, which would lead to an
unplanned medically assisted withdrawal.
5. Severe cognitive impairment that compromises
capacity and/or ability to participate in a group
intervention.
6. Acute stage of severe and enduring mental illness
(schizophrenia, bipolar affective disorder, recurrent
depressive disorder—current episode severe), when
acute symptomatology compromises service user’s
ability to participate in a group intervention.
Trial arms
Treatment as usual Usual detoxification/control com-
prises planning for detoxification, detoxification delivery
and aftercare. Standardised procedures across sites will be
confirmed in phase 1. Service users enter detoxification at
the first available opportunity (likely to be within 4 weeks
from presentation). Whilst waiting for detoxification, they
will meet their key worker (one-to-one) on 3–4 occasions
to maintain motivation and plan aftercare.
Detoxification is medically assisted in the community
as an outpatient, or inpatient, as clinically indicated. The
choice depends on health risk factors and availability of
social support during detoxification. The type of detoxi-
fication has been shown by NICE not to affect treatment
outcomes [4]. Aftercare (following detoxification) in-
cludes peer support groups such as Self-Management
and Recovery Training (SMART) Recovery or Alcoholics
Anonymous (AA), a small number of individual key
worker sessions, pharmacological interventions as ap-
propriate or more comprehensive aftercare group
programme. Participants in both intervention and con-
trol groups will receive all the above elements of usual
care available in the recruiting service. Each participant’s
care pathway will be recorded in detail and analysed for
variability within and between sites as part of the eco-
nomic evaluation (see below), to ensure these are
equivalent across trial arms.
Intervention The intervention provides structured
group preparation (additional to usual care) with the
aim of helping participants regain control over their
drinking, prior to detoxification. Part of this control is
lifestyle modification, which is necessary for maintaining
abstinence post detoxification. Regaining control is
linked with developing new coping skills and enhanced
self-efficacy.
The six sessions are numbered and offered weekly in a
given order. Stabilisation of the amount and pattern of
drinking is a common theme across all the sessions. To
that effect, each session can act as an entry point (i.e. an
open rolling programme group), despite the special
theme covered in depth during the second part. Each
session has two facilitators, lasts for 1 h and is divided
into three parts:
 In the first part (15 min), group rules are established
(as advised in PPI meetings), new members are
introduced, aims of the intervention, in-between ses-
sions practice allocated in previous session reviewed
as are individual targets set for the previous week
are reviewed.
 The second part (30 min, main part) explores the
following themes depending on the session number:
1—understanding habit, addiction and alcohol
dependence; 2—stabilise and control your drinking;
3—lifestyle changes for you and the people around
you; 4—reduction of your drinking; 5—achieving
abstinence; and 6—relapse prevention strategies.
 In the third part (15 min), the group summarises the
main learning points and agrees in-between sessions
practice and targets to be achieved before the next
session. A group work folder will be provided enab-
ling notes and worksheets to be kept together, as
also suggested by PPI meetings.
The number of participants per group at any point is
between two and eight, as this is considered appropriate
for theory-based treatment groups, to reach a balance
between education, treatment, group interactions and fa-
cilitator’s attention to each participant [13]. This max-
imum is unlikely to be reached in the feasibility trial. If
only one participant is present, the session will be of-
fered by one of the facilitators as an individual session.
The duration of 1 h as suggested in PPI, will reduce risk
of withdrawal symptoms and help participants to main-
tain concentration.
Outcome measures
Feasibility outcomes will be (1) Recruitment and reten-
tion rates: we will monitor (monthly) the number of
alcohol-dependent clients accessing services during the
recruitment period of the study, how many meet the eli-
gibility criteria and how many were invited and accepted
into the study and retained in each group for the full 12
months. (2) Compliance with treatment: number of
SPADe sessions attended (for the intervention arm)
using the facilitator’s record of attendance. (3) Data col-
lection and completeness: attendance for assessments
and completeness of instruments; loss to follow-up and
missing data for all outcomes will be analysed.
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A variety of possible outcomes will be used, assessed
at different time points (3, 6 and 12months following
randomisation), so the primary outcome for the main
trial can be identified and sample size calculations con-
ducted, including duration of continuous abstinence
with no incidents of lapse or relapse; percentage of days
of abstinence (PDA) (both self-report using Timeline
Followback method (TLFB)) [22]; and time to relapse
(from stopping alcohol to first day of alcohol use, also as
defined by self-report).
Secondary outcomes will be measured using validated
instruments wherever possible at the same time points as
above:
1. Severity of Alcohol Dependence Questionnaire
(SADQ), a 20-item self-completion questionnaire,
scores range 0 to 60 (16 to 29 indicates moderate
severity, above 30 severe dependence) [23].
2. Alcohol Urge Questionnaire (AUQ), an eight-item
self-completion questionnaire containing three do-
mains of drinking urges: desire for a drink, expect-
ation of positive effect from drinking and inability
to avoid drinking [24].
3. Incentive conflict task (ICT). We have introduced
the ICT as incentive conflict task (ICT), a newly
developed task which models contributors to
relapse (inherent conflict in abstaining drinkers
between the intention to abstain from drinking, and
the desire to drink) [9]. The ICT requires
experimental subjects to abstain from responding
during the presentation of a novel compound
stimulus made up of two visual cues that she/he
has previously learned to signal reward availability
when presented separately. Thus, the task requires
the subject to respond for the monetary reward, but
to withhold responding under conditions in which
an increased size of reward (both positive cues
together) might be reasonably anticipated. In other
words, ICT engages both bottom-up triggers of
reward-seeking and the top-down processes that
normally modulate and veto responses to such trig-
gers. We have suggested that the task thus creates a
conflict between abstaining and responding for re-
ward similar to that experienced by the patients be-
fore relapse and that the impaired ability of
multiple-detoxified patients to perform the task ac-
curately reflects the consequences of detoxification
on top-down control of their behaviour. Alcohol-
dependent patients, as they experience successive
detoxifications and their alcohol dependence in-
creases, become increasingly impaired in perform-
ing the ICT [25].
4. Euro-QoL (EQ-5D-5 L); English version [26], which
is a short questionnaire assessing general healthcare
used in economic evaluations for the calculation of
quality-adjusted life years.
5. Self-reported participation in aftercare activities,
using a specifically developed log, measuring type
and frequency of activity attended, during the
period prior to the follow-up interview.
All instruments will be administered by research assis-
tants in face-to-face assessments with participants.
These assessments will take place at a convenient loca-
tion for each participant, including their home. Research
assistants (RA) will be fully trained to administer all out-
come measures (see Table 1 below).
Randomisation and masking
Once consented, participants will be randomised using a
third-party web-based randomisation system which will
ensure concealed allocation. Participants will be strati-
fied according to the number of previous detoxifications
(> 2 vs ≤ 2) and site. Randomisation will have a random
block size [2–4]. Research assistants will be blind to the
randomisation of the opposite study site and will con-
duct those follow-up interviews. Any breach in blinding/
unmasking, a common problem with single-blind trials,
will be monitored by asking the research assistants to re-
port any such incident, to ensure that the research assis-
tants are not aware, as far as possible, to which group
the individual was allocated in the opposing study site.
Treatment fidelity
Twenty-five percent of the intervention sessions, offered
across both recruitment sites, during the whole duration
of the study recruitment and treatment stage, will be ob-
served and rated using the Yale Adherence and Compe-
tence Scale (YACS II) (2005) [27]. This is a validated
instrument measuring the use of CBT techniques. The
tool can be adapted to the focus of the therapy under in-
vestigation. Furthermore, 10% of the sessions will be ob-
served and rated by an additional independent rater
using YACS II. Group facilitators will complete a
self-assessment form following each session to reflect on
their fidelity to the intervention manual.
Table 1 The use of instruments at different time points
Instruments Baseline 3 months 6 months 12 months
TLFB (previous 90 days) v v v v
SADQ v v v v
AUQ v v v v
ICT v v v v
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Twenty-five percent of the key-working sessions of-
fered to the control group will be audio recorded and be
rated to assess possible contamination between the study
arms using a specifically developed form based on YACS
II items as well as the main objectives of the SPADe
group intervention. Ten percent of those sessions will
also be independently rated.
Statistical analysis
The main analysis will be based on the intention-to-treat
principle considering all randomised clients according to the
arm they were allocated. As the trial is a feasibility study, the
main analysis is to be descriptive and estimate the potential
effect sizes and parameters required for the sample size cal-
culation, rather than formal hypothesis testing.
The feasibility outcomes will be summarised using de-
scriptive statistics where appropriate. The potential pri-
mary and secondary outcomes will be summarised by
arm, as well as completion rates estimated for each out-
come measure. Duration of continuous abstinence, as
measured from randomisation, and the time to relapse,
as measured from the end of the intervention, will be
analysed using a Kaplan-Meier curve and log-rank test.
The percentage of days of abstinence (PDA) will be ana-
lysed using a regression model. Formal hypothesis tests
and confidence intervals will be conducted although due
to the nature of this trial, they will be treated cautiously
and the main focus will be on the completion rate of
outcomes and the estimation of parameters required for
a sample size calculation for the main trial.
Economic evaluation and analysis
The economic evaluation that will run alongside the fu-
ture trial will assess the cost-effectiveness of the SPADe
intervention, compared to usual care, from the NHS and
wider public service perspective. Economic evaluation is
required in the feasibility study to inform decisions
about how costs and outcomes would be measured in
any future definitive trial.
The feasibility study will seek to gain an understanding
of the main resource items for which comprehensive
data collection would be required in the main trial. The
resources involved in delivering the intervention will be
collected from providers and will cover human re-
sources, facilities, materials and overheads, so that full
economic costs and average costs per participant can be
calculated. Usual care (received by both arms) may vary.
Hence, data on care provided will be collected on an in-
dividual client basis from clinic records so that variabil-
ity can be explored both within and between groups.
Alcohol dependence can give rise to significant use of
health, social and criminal justice services. The cost of
implementing SPADe may be offset if it results in in-
creased numbers of successful detoxifications and
consequent reductions in alcohol-related utilisation of
these services. To capture this possible effect, data on ser-
vice utilisation will be gathered retrospectively from par-
ticipants at 3-, 6- and 12-month assessments by
self-report. The Client Service Receipt Inventory, custo-
mised in collaboration with service users, will be used for
this purpose. Included items will cover GP, mental health
services, specialist alcohol services, A&E attendance, in-
patient stays and contact with social and criminal justice
services. Items of service use will be converted to costs
(British pounds, 2017) using nationally validated sources
[28, 29] and national reference costs for secondary care
(https://www.gov.uk/government/publications/nhs-refer-
ence-costs-2012-to-2013). Service use data will be ana-
lysed descriptively to assess validity.
The feasibility study will also explore the properties of
the alternative primary outcomes to assess their value as
measures of effectiveness for the full economic evaluation.
The health-related quality of life outcome for the eco-
nomic evaluation will be EQ-5D-5 L, measured at each as-
sessment point, from which a standardised unit of
measurement—the quality-adjusted life year (QALY)—can
be obtained. A preliminary cost-effectiveness analysis will
be undertaken to determine the likely advantage of con-
ducting a full economic evaluation. Total and per partici-
pant costs will be compared between groups to assess
whether overall there are cost savings associated with the
SPADe intervention, compared to usual care, and how
these compare with client outcomes.
Stage 3—qualitative study
Aim
The qualitative study seeks to understand the experi-
ences of the feasibility trial participants. Although we
are interested in individual interpretations of experi-
ences, recognising that there are many views on the
world all with equal ‘validity’, a critical realist approach
has been chosen as we also seek to uncover practical-
ities, understand key events and important aspects spe-
cifically of trial procedures (recruitment and
randomisation, for example, and then specific aspects of
either the intervention or of treatment as usual), from
the perspectives of individuals involved in the study, that
may inform our approach for a definitive trial.
Method
We will use individual interviews, as being the most ap-
propriate means of assessing participant experience
guided by specific topics and outcomes of interest. The-
matic coding of all qualitative interview data will be
undertaken, to draw out participant perspectives that illu-
minate trial procedures to inform our future approach to
evaluation [30]. This is an approach that we have success-
fully employed in trial feasibility work in the past [31].
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Sampling
A purposive sample of participants across both trial
groups and areas (approximately n = 20) will be inter-
viewed at 3 months to establish experiences of random-
isation, recruitment and initial trial procedures. These
early interviews (wave 1) will select participants by
accessing demographic details and purposefully selecting
individuals across a range of variables, including age,
employment status, length of time in treatment, and se-
verity of dependence; aiming for maximum variation in
the sample. Further variables may be selected for de-
pending on the specific features of individuals recruited
to the study and in consultation with the project steering
group (including PPI input). Follow-up participant inter-
views with the same interviewees will be undertaken at
9 months (completion of the study, wave 2) to give spe-
cific feedback on retention issues and treatment condi-
tions (specifically in relation to the control condition or
receiving the intervention).
Data collection
Interview guides will be developed in consultation with PPI
representatives and following piloting, to capture the range
of possible views, but will be flexibly employed to allow par-
ticipants to discuss experiences and opinions in a way that
is meaningful to them. Thus, although interviews are
semi-structured and focused very much on trial procedures
to inform a future definitive study, we will also consider the
lens of individual experience and understanding in the in-
terpretation of our findings. Qualitative interviews will be
undertaken by the study RA, who will be trained in qualita-
tive interviewing techniques. Qualitative interviews will be
undertaken at treatment premises and timed to coincide
with appointments, where possible, to minimise inconveni-
ence to the participant. All interviews will be audio re-
corded following informed consent. A £10 shopping
voucher will be offered to participants as compensation for
their time commitment per interview they attend (total of
two vouchers). All interviews will be transcribed verbatim,
at which stage transcripts will be fully anonymised. Identify-
ing participant details for follow-up (wave 2) interviews will
be stored on password-protected encrypted computers, ac-
cessible only to members of the study team. Anonymised
transcripts will be password-protected, stored separately,
and will be archived for potential secondary analysis at later
date. Archived transcripts will be kept in fully anonymised
form, conforming to data archiving procedures such as
those of the ESRC UK data archive.
Triangulation
A selected sample of carers and staff involved with the
intervention will be interviewed on study completion. We
anticipate that 5–6 carer interviews and 5–6 staff inter-
views will be sufficient to inform our aim of informing
study procedures and will add to perspectives of partici-
pant experience. Carers and staff will not receive any
monetary compensation for participating in the study.
Thus, these other views will help us to triangulate the
qualitative data and offer a range of different perspectives
that may be useful for meeting our feasibility aims. For ex-
ample, staff may usefully offer practical service-based rec-
ommendations for future trial procedures. Carers will
offer a unique perspective on how participants experience
the intervention which may give an alternative view for
our consideration. The topic guides for these carer and
staff interviews will be finalised following completion of
the participant data collection, in order that emergent
analysis can shape areas for further discussion with staff
and carers. Contextual factors will be included such as
staff descriptions and perceptions of service delivery (local
level contextual factors). Relevant local and national policy
will be monitored for the study duration (macro-level con-
textual factors).
Analysis
Qualitative analysis will thematically compare key expe-
riences between trial groups (https://www.gov.uk/gov-
ernment/publications/nhs-reference-costs-2012-to-2013)
and consider staff experiences across trial areas. Analysis
will be discussed at regular meetings to develop the the-
matic coding scheme and will utilise service user per-
spectives in reaching consensus. Analysis will be led by
one study RA and supervised by CN, who will undertake
independent coding to triangulate perspectives and en-
sure that interpretations are reliable and valid. We con-
sider that our proposed sample size of 20 participants
will be adequate to meet project aims and to achieve
‘saturation’ of coding in terms of the range of likely ex-
periences and views. However, we will continue to sam-
ple in an iterative manner should our emergent analysis
suggest that saturation is not yet reached. Final analysis
will offer in-depth qualitative explanation of the quanti-
tative study findings. Qualitative analysis findings will
therefore inform feasibility questions considered by the
trial steering group and enable a thorough evaluation of
the process of the feasibility study in order to proceed to
a definitive study.
Ethical and research and development reviews
The study was approved by the Health Research Author-
ity (HRA) Research Ethics Committee (REC) (IRAS ID:
213086) for all participating centres. All study personnel
will comply with the MCA 2005 [32] and published re-
search governance guidelines. We anticipate that all par-
ticipants will have the capacity to consent and sufficient
verbal communication skills to take part in the treat-
ment and in the qualitative interview. Informed written
consent will be obtained from all participants. As this is
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a non-invasive intervention, we do not anticipate any ad-
verse events, but we will follow safety reporting guidance
issued by the National Research Ethics Service (UK) for
studies except clinical trials of investigational medicinal
products. The study has been approved by the research
and development (R&D) departments of the relevant
recruiting sites.
Patients and public involvement
The first PPI event was organised in 2014. Advice had
been sought from three service users who had com-
pleted the groups and another service user who did not.
Suggestions included being able to ‘write things down’
and keep in a group work ‘folder’ as well as preference
for face-to-face research assessments. Feeding back re-
sults to service users via service user reps, newsletters,
and peer mentors and on the electronic screen display in
service waiting rooms was also requested and imple-
mented. The concept of randomisation was met with en-
thusiasm by service users and it was felt that people
would be happy to participate in the study. All sugges-
tions were incorporated in the study protocol and dis-
semination plans. There were two discussion groups
with staff at two treatment centres where the need for
research outcomes and the practicalities of running trials
was met with eagerness by staff.
A second PPI event took place in 2015 at the service
users’ forum where the feasibility study design was dis-
cussed. Suggestions were made about the provision of
written information about the group, the importance of
rules for acceptable behaviour during the group sessions,
the maximum number of sessions and participants and
the aftercare planning as part of preparation. One ser-
vice user expressed interest in being a collaborator in
the study, and he became part of our study steering
committee. Following the PPI event, existing informa-
tion about the group was reviewed, modified and ap-
proved by the service users’ forum.
Discussion
The SPADe trial builds on previous work completed by
the authors, which has shown that a structured prepar-
ation approach prior to alcohol detoxification can im-
prove overall capacity of the treatment pathway by
increasing patients’ engagement and by reducing drop-
out rates from detoxification [6, 15]. Two open studies
indicated that the intervention improves outcomes (con-
tinuous abstinence) at 3 [15] and 6months [16]. A quali-
tative study with service users who have completed the
intervention [17] and a process study [33] have indicated
that the theory-based intervention works as expected
and predicted by the underpinning theory.
This feasibility trial will help us to answer questions of
acceptability of the intervention by wider group of service
users, carers and service providers. It will provide evidence
on implementation issues such as the training, supervision
and overall support required to implement the interven-
tion. In more detail will enable us to do the following:
1. Measure the number of eligible participants and
those not, willingness of clinicians to recruit
participants, recruitment rate, loss to follow-up, ad-
herence to the intervention and standard deviation
of the primary outcome measures. This will ultim-
ately inform the sample size calculation for a multi-
centre clinical trial.
2. Determine the acceptability of randomisation to
service users, through its effect on recruitment,
dropout rates and via qualitative interviews.
3. Determine, through response rates to
questionnaires, the appropriateness and the
acceptability of the outcome measures to service
users, in order to explore the suitability of our
chosen secondary outcome measures, that is,
percentage of days of abstinent, service use and
health-related quality of life.
4. Estimate the time needed to collect and analyse
baseline and outcome data
5. Explore the utility of the health-related quality of
life instrument (EQ-5D-5 L) (see the ‘Outcome
measures’ section) in allowing the estimation of
quality-adjusted life years in the sample.
The development of the intervention manual, fidelity
checks (standardised measures and self-reflection tools
scored by two assessors, one an independent) and quality
monitoring of the TAU key-working sessions are consist-
ent with the recommendations of the Treatment Fidelity
Workgroup of the NIH Behaviour Change Consortium
[34]. This group recommended five broad areas in which
fidelity could be enhanced during clinical trials: study de-
sign, training of treatment providers, delivery of treatment,
receipt of treatment and enactment of treatment skills.
Specific suggestions to avoid threats to fidelity included
the following: development of a treatment manual that in-
cludes information about treatment dose (length and
number of contacts) and specific content of each contact,
standardisation of therapist training, monitoring the inter-
vention with fidelity checklists and inclusion of strategies
to measure the recipient’s comprehension and enactment
of the intervention principles addressed.
The feasibility RCT will provide support for the design
and execution of a future full RCT by testing different pri-
mary and secondary outcomes at different time points and
should allow estimation of the sample size required. In
addition, the use of ICT will explore further the potential
harm minimisation role of structured preparation prior to
detoxification by improving cognitive functioning. Finally,
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the collection of data regarding aftercare treatment en-
gagement will provide further evidence on the potential
positive role of our structured preparation in aftercare
participation and the associated exposure to the psycho-
social treatment ingredients recommended by current
treatment guidelines.
Trial status
At the time of the manuscript submission, the trial has
started recruitment of participants. At the time of manu-
script acceptance, recruitment was completed (June 2018).
Abbreviations
A&E: Accident and emergency department; AA: Alcoholics Anonymous;
AUD: Alcohol use disorders; AUQ: Alcohol Urge Questionnaire; CBT: Cognitive
behaviour therapy; HRA: Health Research Authority; ICT: Incentive conflict
task; MRC: Medical Research Council; NHS: National Health Service;
PDA: Percentage of days abstinent; PPI: Patient and public involvement;
PRIME: Plans, Responses, Impulses, Motives, Evaluations; RA: Research
assistant; RCT: Randomised controlled trial; REC: Research Ethics Committee;
SADQ: Severity of Alcohol Dependence Questionnaire; SMART: Self-
Management and Recovery Training; SPADe: Structured Preparation for
Alcohol Detoxification; TAU: Treatment as usual; TLFB: Timeline Followback
method; YACS: Yale Adherence and Competence Scale
Acknowledgements
We thank the service users’ representatives participating in this study. We
thank the study sponsor Surrey and Borders Partnership NHS Foundation
Trust, the Camden and Islington NHS Foundation Trust, collaborating
researcher assistant and therapists and members of the Steering
Committees. The views expressed are those of the author(s) and not
necessarily those of the UK National Health System, the NIHR or the
Department of Health.
Funding
This study is supported by the UK National Institute for Health Research
(NIHR) under its Research for Patient Benefit (RfPB) Programme (grant
reference number PB-PG-0815-20014). The funder of the study had no role in
study design, data collection, data analysis, data interpretation, or writing of
the report. The authors had full access to all the data in the study and had
final responsibility for the decision to submit for publication.
Availability of data and materials
The datasets generated and/or analysed during the current study are
available from the corresponding author on reasonable request.
Authors’ contributions
CK has overall management of the research project, developed the
intervention manual, will supervise the therapists and will contribute to all
outputs such as papers in conference and journals. He has contributed to
the writing of the current paper. BH is a research assistant on the project,
conducts the assessments and interviews with participants and carers and
has contributed to the paper content and its preparation for submission. HG
is the lead for the health economics part of the project and will oversee the
analysis of those data. CN is the lead for the qualitative study. She will train
the service users and research assistants for the qualitative interviews and
will supervise the analysis of the data. VM is the overall project manager. She
is responsible for the coordination of study recruitment across sites, the
supervision and support of the research assistants. AC is the project
statistician. He is responsible for all statistical aspects including
randomisation and analysis of quantitative data. RH and ALH contributed
into the methodological aspects of the project and will participate in data
analysis and dissemination of the findings. BP is responsible for coordination
of recruitment from one of the participating services. TD is responsible for
the training and appropriate use of the ICT. All authors read and approved
the final manuscript.
Authors’ information
CK is a consultant psychiatrist in addictions; his PhD is on psychological
interventions in substance misuse. BH is a research assistant. HG is a professor
of health economics. CN is a senior lecturer in mental health and a research
fellow of the Society for the Study of Addiction. VM is a research fellow and
senior programme co-ordinator. AC is a senior lecturer in statistics. RH is head
of the Leicester Medical School and a professor of Public Health Medicine. ALH
is a professor in psychiatry, chair of addiction Biology and consultant psychiatrist
in addictions. BP is a consultant psychiatrist in addictions. TD is a professor in
experimental psychology.
Ethics approval and consent to participate
The study was approved by the HRA REC (IRAS ID:213086) for all





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Research and Development, Abraham Cowley Unit, Surrey and Borders NHS
Foundation Trust, Surrey, Chertsey KT16 0AE, UK. 2University of Surrey, 388
Stag Hill, Guildford GU2 7XH, UK. 3Norwich Medical School, University of East
Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. 4University of East
Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. 5University of Leicester,
University Road, Leicester LE1 7RH, UK. 6Imperial College London, Burlington
Danes Building, Hammersmith Campus, 160, Du Cane Road, London W12
0NN, UK. 7Camden and Islington NHS Foundation Trust, St Pancras Hospital,
4 St Pancras Way, Kings Cross, London NW1 0PE, UK. 8University of Sussex,
Falmer, Brighton BN1 9RH, UK.
Received: 15 February 2018 Accepted: 9 April 2019
References
1. Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, Giovino GA,
West R, Hall W, Griffiths P, Ali R, Gowing L, Marsden J, Ferrari AJ, Grebely J,
Farrell M, Degenhardt L. Global statisitcs on alcohol, tobacco and illicit drug
use: 2017 status report. Addiction. 2018;113:1905–26.
2. England Public Health. Alcohol treatment in England 2013–14 2014.
3. Public Health England. Alcohol and drug treatment in England: the picture
from the 2016–17 data. 2017.
4. Alcohol use disorders: diagnosis, assessment and management of harmful
drinking and alcohol dependence. London: NICE, 2010.
5. Alexander PK, Roebuck MC, French MT, Chitwood DD, McCoy CB. Problem
drinking, health services utilization, and the cost of medical care. Recent
Dev Alcohol. 2001;15:285–98.
6. Noel X, Van der Linden M, Schmidt N. Supervisory attentional system in
non-amnesic alcoholic men. Arch Gen Psychiat. 2001;58:1152–8.
7. Kouimtsidis C, Drable K, Ford L. Implementation and evaluation of a three
stages community treatment programme for alcohol dependence. A short
report. Drugs. 2012;19(1):81–3.
8. Duka T, Townshend JM, Collier K, Stephens DN. Impairment in cognitive
functions after multiple detoxifications in alcoholic inpatients. Alcohol Clin
Exp Res. 2003;27(10):1563–72.
9. Loeber S, Duka T, Welzel H, Nakovics H, Heinz A, Flor H, et al. Impairment of
cognitive abilities and decision making after chronic use of alcohol: the
impact of multiple detoxifications. Alcohol Alcohol. 2009;44(4):372–81.
10. Duka T, Trick L, Nikolaou K, Gray MA, Kempton MJ, Williams H, et al. Unique
brain areas associated with abstinence control are damaged in multiply
detoxified alcoholics. Biol Psychiatry. 2011;70(6):545–52.
11. Loeber S, Duka T, Welzel Márquez H, Nakovics H, Heinz A, Mann K, et al.
Effects of repeated withdrawal from alcohol on recovery of cognitive
Kouimtsidis et al. Pilot and Feasibility Studies            (2019) 5:59 Page 10 of 11
impairment under abstinence and rate of relapse. Alcohol Alcohol. 2010;
45(6):541–7.
12. Duka T, Townshend JM, Collier K, Stephens DN. Kindling of withdrawal: a
study of craving and anxiety after multiple detoxifications in alcoholic
inpatients. Alcohol Clin Exp Res. 2002;26(6):785–95.
13. Bieling P, McCabe RE, Antony MM. Cognitive-behavioral therapy in groups.
New York: Guilford Press; 2006.
14. Raistrick D, Heather N, Godfrey C. Review of the effectiveness of treatment
for alcohol problems. London: National Treatment Agency for Substance
Misuse; 2006.
15. Kouimtsidis C, Ford L. A staged programme approach for alcohol
dependence: cognitive behaviour therapy groups for detoxification
preparation and aftercare; preliminary findings. Drugs. 2011;18(3):237–9.
16. Kouimtsidis C, Sharma E, Smith A, Charge KJ. Structured intervention to
prepare dependent drinkers to achieve abstinence; results from a cohort
evaluation for six months post detoxification. J Subst Abus. 2015. https://
doi.org/10.3109/14659891.2015.1029020.
17. Croxford A, Notley C, Maskrey V, Holland R, Kouimtsidis C. An exploratory
qualitative study seeking participant views evaluating group cognitive
behavioural therapy group preparation for alcohol detoxification. J Subst
Abus. 2015;20(1):61–8.
18. West R. Theory of addiction. London: Blackwell Publishing; 2006.
19. Bandura A. Self-efficacy in changing societies. London: Cambridge
University Press; 1995.
20. Koob GF, leMoal M. Drug abuse: hedonic homeostatic dysregulation.
Science. 1997;278:52–8.
21. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-
reported ethanol consumption. In: Allen J, Litten RZ, editors. Measuring
alcohol consumption: psychosocial and biological methods. Totowa:
Humana Press; 1992. p. 41–72.
22. Craig P, Dieppe P, Macintyre S, Michie S, et al. Developing and evaluating
complex interventions: the new Medical Research Council guidance. Br Med
J. 2008;337:a1655.
23. Stockwell T, Murphy D, Hodgson R. The severity of alcohol dependence
questionnaire: its use, reliability and validity. Br J Addict. 1983;78:145–55.
24. Bohn M, Krahn DD, Stachler BA. Development and initial validation of a
measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res.
1995;19:600–6.
25. Duka T, Stephens DN. Repeated detoxification of alcohol-dependent
patients impairs brain mechanisms of behavioural control important in
resisting relapse. Curr Addict Rep. 2014;1:1–9. https://doi.org/10.1007/
s40429-013-0009-0.
26. EQ-5D-5 L User Guide. Basic information on how to use the EQ-5D-5 L
instrument. https://euroqol.org/eq-5d-instruments/eq-5d--5l-about/.
Accessed 4 July 2017.
27. Nuro KF, Maccarelli L, Baker SM, Martino S, Rounsaville BJ, Carroll KM. Yale
Adherence and Competence Scale (YACS-II) guidelines. West Haven: Yale
University Psychotherapy Development Center. Substance Abuse Center; 2005.
28. Chisholm D, Knudsen HC, Amaddeo F, Gaite L, van Wijngaarden B, Epsilon
study group. Client socio-demographic and service receipt inventory -
European version : development of an instrument for international research.
Br J Psychiatry 2000; 177: s28-s33. doi: https://doi.org/10.1192/bjp.177.39.s28.
29. Curtis L. Unit costs of health and social care 2017. www.pssru.ac.uk
30. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;
3(2):77–101 ISSN 1478-0887. Available from: http://eprints.uwe.ac.uk/11735.
31. Notley C, Christopher R, Hodgekins J, Byrne R, French P, Fowler D.
Participant views on involvement in a trial of social recovery cognitive–
behavioural therapy. Br J Psychiatry. 2015;206(2):122 7. https://doi.org/10.
1192/bjp.bp.114.146472.
32. Mental Capacity Act 2005. http://www.mentalhealthlaw.co.uk/ Mental
Capacity Act 2005. 2014. Accessed 4 July 2017.
33. Kouimtsidis C, Charge KJ, Moch JP, Stahl D. Abstinence preparation group
intervention for dependent alcohol users. How does it work? Results of a
process study. J Subst Abus. 2017;22(2):149–55. https://doi.org/10.3109/
14659891.2016.1153164.
34. Bellg AJ, Borrelli B, Resnick B, Hecht J, Minicucci DS, Ory M, Czajkowski S.
Enhancing treatment fidelity in health behavior change studies: best
practices and recommendations from the NIH Behavior Change
Consortium. Treatment Fidelity Workgroup of the NIH Behavior Change
Consortium. Health Psychol. 2004;23(5):443–51.
Kouimtsidis et al. Pilot and Feasibility Studies            (2019) 5:59 Page 11 of 11
